1. Home
  2. FRAF vs KOD Comparison

FRAF vs KOD Comparison

Compare FRAF & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Financial Services Corporation

FRAF

Franklin Financial Services Corporation

HOLD

Current Price

$58.51

Market Cap

261.9M

Sector

Finance

ML Signal

HOLD

Logo Kodiak Sciences Inc

KOD

Kodiak Sciences Inc

HOLD

Current Price

$35.15

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRAF
KOD
Founded
1906
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
261.9M
2.8B
IPO Year
1995
2018

Fundamental Metrics

Financial Performance
Metric
FRAF
KOD
Price
$58.51
$35.15
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$35.43
AVG Volume (30 Days)
20.7K
524.8K
Earning Date
04-23-2026
05-14-2026
Dividend Yield
2.46%
N/A
EPS Growth
88.84
N/A
EPS
1.48
N/A
Revenue
N/A
N/A
Revenue This Year
$14.44
N/A
Revenue Next Year
$6.95
N/A
P/E Ratio
$38.60
N/A
Revenue Growth
N/A
N/A
52 Week Low
$33.44
$3.35
52 Week High
$60.00
$47.84

Technical Indicators

Market Signals
Indicator
FRAF
KOD
Relative Strength Index (RSI) 58.37 39.39
Support Level $54.63 $32.93
Resistance Level $58.77 $46.72
Average True Range (ATR) 1.80 2.69
MACD 0.06 -0.72
Stochastic Oscillator 80.06 16.94

Price Performance

Historical Comparison
FRAF
KOD

About FRAF Franklin Financial Services Corporation

Franklin Financial Services Corp is a bank holding company based in the United States. It is engaged in general commercial, retail banking, and trust services normally associated with community banks. It offers a broad range of banking services to businesses, individuals, and governmental entities, which include accepting and maintaining cheques, savings, and time deposit accounts, providing investment and trust services, making loans and providing safe deposit facilities. The bank also performs personal, corporate, pension and fiduciary services through its Investment and Trust Services Department.

About KOD Kodiak Sciences Inc

Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.

Share on Social Networks: